Table 3 Details of different experimental groups of mice for in vivo study
Experimental group (n = 8) | Treatment details | Route of Administration |
|---|---|---|
PBS | 100 µL of PBS/mice | Oral + nasal (50 µL each route) |
WT L. lactis (1 × 109 CFU/mice) | Empty L. lactis (NZ9000) in 100 µL PBS/mice | Oral + nasal (50 µL each route) |
rL. lactis (1 × 109 CFU/mice) | Nisin-induced rL. lactis harbouring pSec-MuIFNλ3 plasmid in 100 µL PBS/mice | Oral + nasal (50 µL each route) |
rMuIFNλ3 (1 μg/mice) | Freund’s Adjuvant (FA) emulsified purified rMuIFNλ3 protein (expressed in E. coli) | Subcutaneously (100 µL) |